ACE inhibition and COVID-19 – a Mendelian Randomization study
Preprint from new study now available on-line
A study from Gill et al has found no evidence to support the hypothesis that the commonly used hypertension drugs known as ACE inhibitors may be of special relevance for COVID-19 patients, potentially increasing severity of the disease via regulation of the SARS-CoV-2 cellular entry protein, ACE2 (angiotensin-converting enzyme 2). Importantly, they concluded that their findings do not support a change in ACE inhibitor medication use without clinical justification.
Prior to final publication, the authors have made a preprint manuscript from this study available online in order to share this important data with the research community:
Gill et al, “ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study“, medRxiv2020.04.10.20059121 – LINK
What the study adds to existing knowledge
Used human genetic variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 expression and circulating ACE2 levels.
The data does not support the hypothesis that ACE inhibitors have effects on ACE2 expression.
Found some support for an association of genetic liability to type 2 diabetes mellitus with higher lung ACE2 expression and plasma ACE2 levels, but evidence was inconsistent across studies.
The Olink perspective
The plasma ACE2 protein measurements used in this study were made using the ACE2 assay that forms part of our 92-plex Olink CARDIOVSACULAR II panel. Prior to using the Olink ACE2 assay data in the study, the investigators used genetic data to validate the assay’s targeting of ACE2, which may be useful information for other other protein studies within the COVID-19 area.